ストックスクリーナーアプリを入手
20.02
4.87%
0.93
前日終値:
$19.09
開ける：
$18.91
24時間の取引高:
254.92K
Relative Volume:
0.45
時価総額：
$1.80B
収益：
当期純損益:
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
1週間 パフォーマンス:
-5.88%
1か月 パフォーマンス:
-30.75%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$0.00
$0.00
1週間の範囲:
$17.86
$22.02
52週間の値動き範囲:
$17.86
$32.00
Braveheart Bio, Inc. Common Stock Stock (BRVE) Company Profile
Compare BRVE vs VRTX, MRNA, REGN, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BRVE
Braveheart Bio, Inc. Common Stock
|
20.02 | 1.80B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
510.08 | 129.29B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
225.00 | 89.83B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
746.54 | 76.86B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
825.03 | 51.88B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.76 | 40.67B | 742.00K | -1.37B | -1.07B | -7.0731 |
Braveheart Bio, Inc. Common Stock Stock (BRVE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-08-31 | 開始されました | Cantor Fitzgerald | Overweight |
| 2026-08-31 | 開始されました | Goldman | Buy |
| 2026-08-31 | 開始されました | Jefferies | Buy |
| 2026-08-31 | 開始されました | Stifel | Buy |
| 2026-08-31 | 開始されました | TD Cowen | Buy |
Braveheart Bio, Inc. Common Stock (BRVE) 最新ニュース
Braveheart Bio, Inc. Common Stock (NASDAQ: BRVE) Stock Price, News & Analysis - Kalkine
Braveheart Bio, Inc. (NASDAQ:BRVE) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Braveheart Bio, Inc. Common Stock (NASDAQ: BRVE) Stock Price, News & Analysis - kalkine.ca
OrbiMed's stake in Braveheart Bio (BRVE) falls without selling shares - Stock Titan
Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
AH Bio Fund IV Discloses Investment at Braveheart Bio with 11.4% Stake - TradingView
Braveheart Bio CFO Acquires 27,777 Shares for $500,000. Is This a Signal BRVE IPO Is a Success? - The Motley Fool
Braveheart Bio Chairman Chris Viehbacher Buys $1.5M Shares at IPO. What Does This Mean for Investors? - The Motley Fool
Braveheart Bio CEO Travis Murdoch Buys 83,333 Shares for $1.5 Million. Is This a Buy Signal for Investors? - The Motley Fool
Braveheart Bio, Inc. Common Stock (BRVE) Stock Price Today: $27.43 - Gotrade
Braveheart Bio Announces Closing of Upsized Initial Public - GlobeNewswire
Braveheart Bio raises $439.9M in upsized Nasdaq IPO - Investing.com
Braveheart Bio closes $439.9 million IPO on Nasdaq - Investing.com
Braveheart Bio Insider Bought Shares Worth $499,986, According to a Recent SEC Filing - Yahoo Finance
Heart drug developer Braveheart Bio surges on public debut after upsized IPO - Seeking Alpha
Braveheart Bio Announces Pricing of Upsized Initial Public Offering - The Manila Times
Braveheart Bio Shares Rise After Market Debut - Yahoo Finance
Braveheart Bio Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Braveheart Bio shares surge 68% in New York trading debut - Investing.com
Braveheart Bio (Nasdaq:BRVE)Stock Analysis - Simply Wall Street
Braveheart Bio, Inc. (BRVE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Braveheart Bio Expects Nasdaq Debut Aug. 6 After $18 IPO - Stock Titan
Braveheart Bio prices IPO at $18 per share, raises $382.5M - Investing.com
Braveheart Bio, Inc. IPO Analysis: Financial Outlook, Broker Coverage and Listing Prospects - Minichart
Funding Roundup: Braveheart, Attovia, Vogenx All Announce IPO’s - Pharmaceutical Executive
Braveheart Bio Readies $300 Million IPO Plan (BRVE) - Seeking Alpha
Braveheart Bio, Attovia seek $275M and $182M in U.S. IPOs - Seeking Alpha
Braveheart Bio seeks $318.8M in IPO for heart drug - Investing.com
Braveheart Bio, Inc. Common Stock (BRVE) 財務データ
Braveheart Bio, Inc. Common Stock (BRVE) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
Braveheart Bio, Inc. Common Stock (BRVE) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Chimovits Erez | Director |
Aug 07 '26 |
Buy |
18.00 |
1,940,000 |
34,920,000 |
11,901,826 |
| ORBIMED ADVISORS LLC | Director |
Aug 07 '26 |
Buy |
18.00 |
1,940,000 |
34,920,000 |
11,901,826 |
| Forbion Growth Opportunities F | 10% Owner |
Aug 07 '26 |
Buy |
18.00 |
1,920,000 |
34,560,000 |
11,640,546 |
| Forbion Growth Opportunities F | 10% Owner |
Aug 07 '26 |
Buy |
18.00 |
1,680,000 |
30,240,000 |
10,185,478 |
| Rickey James Paul | Chief Financial Officer |
Aug 07 '26 |
Buy |
18.00 |
27,777 |
499,986 |
520,927 |
| Viehbacher Christopher | Director |
Aug 07 '26 |
Buy |
18.00 |
83,333 |
1,499,994 |
609,519 |
| Malek David I | Director |
Aug 07 '26 |
Buy |
18.00 |
4,166 |
74,988 |
533,845 |
| Anderson Michele A. | Chief Development Officer |
Aug 07 '26 |
Buy |
18.00 |
1,111 |
19,998 |
332,161 |
| Murdoch Travis | CEO and President |
Aug 07 '26 |
Buy |
18.00 |
83,333 |
1,499,994 |
2,940,670 |
| Lubner David Charles | Director |
Aug 07 '26 |
Buy |
18.00 |
55,555 |
999,990 |
55,555 |
0.41%
3.98%
大文字化:
|
ボリューム (24 時間):